The Society for Immunotherapy of Cancer (SITC) hosted the "Novel Multi-Targeted Therapeutic Platforms" program during the SITC 2019 Annual Meeting on November 6, 2019. Available here are the presentation slides and video from "Session 3: Clinical Applications of Multi-Targeted Therapeutic Platforms."Program SummaryWith the approval of the first bispecific T-cell engager in 2018, and with many more such multi-targeted antibodies in clinical trials, there has been a resurgence of interest in these multi-functional platforms. Other related platforms, such as cytokine fusions and CAR T cell approaches, are also making their mark on the cancer treatment landscape. As these agents make their way into the clinic, however, many important scientific and clinical questions have been raised. During this half-day program, multi-targeted therapeutic platforms were discussed by experts in the field.Program Organizers
To view the entire program schedule (including presenter permission to post) please click here.
Meeting: SITC 34th Annual Meeting; Industry Program: Novel Multi-Targeted Therapeutic Platforms; Session 3: Clinical Applications of Multi-Targeted Therapeutic Platforms; Presenter: R. Angelo de Claro, MD – U.S. Food and Drug Administration; Date: November 6, 201900:18:58
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com